Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

IMAC Holdings Inc (OQ:BACK)

Business Focus: Hospitals, Clinics & Primary Care Services

Sector:  Healthcare Industry:  Healthcare Facilities & Services
 
See Regulatory Filings on SEC
Company Contact
Address: 1605 Westgate Cir
BRENTWOOD TN 37027
Tel: 1-212-8383777
Website: https://imacregeneration.com
IR: See website
Key People
Jeffrey S. Ervin
Chairman of the Board, Chief Executive Officer, Co-Founder
Matthew C. Wallis
Co-Founder, Director
Sheri Gardzina
Chief Financial Officer
Business Overview
IMAC Holdings, Inc. is a clinical research and commercialization company. The Company is focused on innovative medical advancements and care in the oncology, neurological, and orthopedic medical specialties. The Company is focused on providing natural, non-opioid solutions to pain as consumers demand conservative treatments for an aging population. Its Investigational New Drug division conducted a clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinson's disease. The Company is also engaged in providing the precision medicine business. The Company's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDTs are utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer.
Financial Overview
For the fiscal year ended 31 December 2023, IMAC Holdings Inc revenues was not reported. Net loss applicable to common stockholders excluding extraordinary items decreased 45% to $6.5M. Lower net loss reflects Labor & Related Expenses in SGA decrease of 67% to $1.3M (expense), G/L on Sale of Tangible & Intangible FA decrease of 24% to $3.4M (expense), Selling/Gdmin Expense decrease of 41% to $1.5M (expense).